Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

PHASE3CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

Not specified

Conditions
Brain NeoplasmsCarcinoma, Non-Small-Cell LungMetastases, Neoplasm
Interventions
DRUG

Motexafin Gadolinium

Trial Locations (92)

Unknown

Phoenix

Fort Smith

Little Rock

Berkeley

Concord

Greenbrae

Los Angeles

Montebello

Sacramento

Stanford

Aurora

Hartford

New Haven

Chicago

Fort Wayne

Indianapolis

Shreveport

Baltimore

Washington D.C

Boston

Detroit

Grand Rapids

Minneapolis

St Louis

Omaha

Camden

Morristown

Albuquerque

New York

Rochester

Akron

Cleveland

Columbus

Hershey

Philadelphia

Knoxville

Nashville

Houston

Laredo

San Antonio

Tyler

Charlottesville

Madison

Milwaukee

Liverpool

St Leonards

Wollongong

Herston

Woollongabba

East Melbourne

Footscray

Geelong

Heidelberg

Linz

Vienna

Antwerp

Brussels

Haine-Saint-Paul

Leuven

Calgary

Edmonton

Halifax

Hamilton

Kingston

London

Ottawa

Toronto

Montreal

Québec

Sherbrooke

Caen

Lille

Lyon

Montbéliard

Nice

Pierre-Bénite

Rennes

Saint-Herblain

Vandœuvre-lès-Nancy

Villejuif

Aachen

Berlin

Essen

Freiberg

Hamburg

Heidelberg

Herne

Magdeburg

München

Gravenhage

Heerlen

Rotterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmacyclics LLC.

INDUSTRY

NCT00054795 - Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) | Biotech Hunter | Biotech Hunter